Myriad Genetics, Inc. (MYGN)
$4.15+1.72%Close
BUYRECOVERY · day 33
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $392M
- Beta
- 1.64
- P/E (TTM)
- -3.47
- Short % float
- 9.94%
- Days to cover
- 4.3
- SI change
- -8.6%
- 1W
- -3.04%
- 1M
- +6.96%
- vs SPY 1W
- -2.06%
- vs SPY 1M
- +5.09%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$56.7BBULLQ 30$395.65-0.23%
- GHSELLGuardant Health, Inc.$21.8BBEARQ 23$162.09+0.56%
- QGENBUYQiagen N.V.$9.4BRECOVERYQ 16$45.44+0.26%
- BLLNSELLBillionToOne, Inc.$4.3BRECOVERYQ -7$94.44+3.64%
- VCYTBUYVeracyte, Inc.$3.4BBEARQ 14$43.11+0.93%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$15.85+0.32%
- FLGTSELLFulgent Genetics, Inc.$598MRECOVERYQ 13$21.06-0.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 5
- GROWTH
- 38
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-19.6%
REV YoY-
ROE-32.6%
EPS YoY-
ROA-17.6%
GROSS69
OP-12
NET-14
[VALUATION]
P/E TTM-3.47
P/E FWD-
SECTOR PE20.48
INDUSTRY PE32.29
P/B1.29
P/FCF-
EV/EBITDA-10.89
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E69.27
ALTMAN Z-
CURR RATIO2.21
ND/EBITDA-
BETA1.64
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
BUY
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR1.4
TRADES147
[REGIME]FULL HISTORY
RECOVERY
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on MYGN?
- LOPJLB’s latest quantitative signal on Myriad Genetics, Inc. (MYGN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is MYGN in?
- Myriad Genetics, Inc. (MYGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Myriad Genetics, Inc. (MYGN) do?
- Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, womenâs health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, …